The ENDO 2022 Annual Conference

Fezolinetant reduces hot flashes during menopause

Roshini Claire Anthony, 20220801140001

The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.

Timing of liquid LT4 intake doesn’t impact bioavailability

Elvira Manzano, 20220801000000

Bioavailability studies presented at ENDO 2022 showed that patients with hypothyroidism can safely take the liquid formulations of levothyroxine (LT4) 15 or 30 minutes before meals, without having to worry about food effect on bioavailability.

Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD

Audrey Abella, 20220727100000

In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.

Empagliflozin shows promise for chronic SIAD-induced hyponatremia

Audrey Abella, 20220726100000

The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.

10 percent long-term weight loss with lifestyle management, medication in overweight/obese patients

Obese/overweight patients incur 10 percent long-term weight loss with lifestyle management, medication

Roshini Claire Anthony, 20220725150001

Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.

Prediabetes may up MI, PCI, CABG risk

Roshini Claire Anthony, 20220721180001

Individuals with prediabetes appear to be at an elevated risk of developing myocardial infarction (MI) as well as requiring coronary interventions, according to a study presented at ENDO 2022.

Testosterone therapy safe for the heart, but some experts disagree

Elvira Manzano, 20220708000000

Testosterone therapy appeared safe for the heart in men with hypogonadism, according to a meta-analysis of 35 placebo-controlled trials presented at ENDO 2022. However, experts have differing opinions on the findings.

Diabetes status may influence long-term survival in metastatic breast cancer

Roshini Claire Anthony, 20220706180001

Long-term overall survival (OS) in patients with metastatic breast cancer (MBC) may be influenced by diabetes status, according to a retrospective study presented at ENDO 2022.